Industry observation: Benefiting from the expansion of pharmaceutical companies, a number of pharmaceutical machinery companies increased their business in the biomedical sector in the first three quarters

In the first three quarters of this year, with the gradual relief of the impact of the epidemic and the cost control challenges faced by pharmaceutical companies under the trend of “quality improvement and cost reduction”, news about pharmaceutical companies’ CDMO and other fields
.
In this context, it has also led to the growth of the performance of many upstream pharmaceutical equipment companies
.
Pharmaceutical equipment (picture source: Pharmaceutical Network) The first three quarters of the pharmaceutical companies to accelerate the expansion of production.
On August 18, 2021, CDMO Boten shares announced plans to acquire 70% of Yuyang Pharmaceutical for 171.
5 million yuan
.
Through this transaction, Proton will have three chemical raw material drug CDMO production bases in Chongqing Changshou, Jiangxi Yichun and Hubei Yingcheng, and the production capacity will be further expanded to 2000m3
.
On April 8, BeiGene Guangzhou Biopharmaceutical Production Base was approved to carry out the commercial production of the monoclonal antibody PD-1 product Baizean (Tilelizumab)
.
The base covers an area of ​​more than 100,000 square meters and has been approved for 8,000 liters of production capacity for commercial production to produce and supply tislelizumab for the Chinese market
.
On April 2 this year, Tuoxin Pharmaceutical announced that it intends to raise 395 million yuan to expand production, research and development and supplement working capital.
Among them, the nucleoside series of specialty APIs and pharmaceutical intermediates construction project will add 2,000 tons after completion.
/Year capacity
.
In addition, since 2021, a number of domestic vaccine companies have actively deployed production capacity construction, including measures such as promoting the construction of their own factories, to ensure vaccine production capacity and subsequent supply
.
As for the reasons for the expansion of pharmaceutical companies, the analysis believes that on the one hand, the impact of the epidemic is gradually alleviating, and domestic vaccines, biomedicine and other industries are ushering in a strong recovery.
Pharmaceutical companies have taken measures to expand their own production capacity, or re-distribute corporate resources based on existing production capacity.
, In order to adapt to the future drug development model
.
On the other hand, in the context of the successive implementation of policies such as the normalization of centralized procurement and the consistency evaluation of generic drugs, "improving quality and reducing costs" has become a major trend.
For domestic pharmaceutical companies, they are not only facing a substantial "half cut" in drug prices.
, And also need to deal with the challenges of rising raw material prices and rising labor costs, which also means that the cost control ability of pharmaceutical companies is facing a big test
.
For example, Anglikang also pointed out in the announcement that “in recent years, domestic policies such as the consistency evaluation of generic drugs, centralized drug procurement and related approvals have been implemented, and'improving quality and reducing costs' has become the main theme now and for a long time to come.

For domestic pharmaceutical companies,'centralized procurement' makes generic drug competition more focused on the cost side, while APIs are the core of production costs, with the integration of'intermediates + APIs + preparations' of high-quality and low-cost APIs The competitive advantages of enterprises are more obvious, and they have obtained greater living space accordingly
.
In this context, preparation enterprises, out of consideration of the safety of the upstream supply chain and maintaining competitiveness, have deployed the production of raw materials and actively seized the elements of the industrial chain
.
" The business growth of the biomedical sector of a number of pharmaceutical machinery companies.
In the context of the expansion of production by pharmaceutical companies, the demand for upstream pharmaceutical equipment, especially biomedical equipment, is growing rapidly, and the industry has ushered in a new round of opportunities.
This can also be seen from the performance of listed companies.
Be reflected
.
For example, the performance forecast for the first three quarters of 2021 released by Xinlai Yingcai on October 12 shows that the company's net profit is 115 to 130 million yuan, a year-on-year increase of 83.
52%-107.
45%
.
Regarding performance growth, the company mentioned that “benefiting from the rapid expansion of domestic vaccine and pharmaceutical manufacturers, the company’s biomedical sector business has grown rapidly
.
” In its recent three-quarter report, Tofflon predicted that the net profit for the first three quarters of 2021 would be 5.
19.
RMB-562 million, a year-on-year increase of 80%-95%
.
The company said that its new products and new markets in various business segments have gradually shown results over the years.
Among them, there are many products in the biomedical sector, such as biomacromolecules and cell equipment, which have grown steadily
.